Skip to Main Content

Advertisement

Skip Nav Destination

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Blood (2021) 137 (3): 323–335.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement